Inadequate Production Research Articles

The Effects of Maternal Subclinical Hypothyroidism on Fetal Thymus Size: A Prospective Study

Objective: This study investigated the impact of maternal subclinical hypothyroidism on fetal thymus size and development and explored how inadequate thyroid hormone production in pregnant women affects the fetal thymus. Methods: Conducted at the Giresun Obstetrics, Gynecology, and Pediatrics Training and Research Hospital, this case–control study involved 86 pregnant women, 43 with hypothyroidism and 43 without. Maternal thyroid function was assessed using TSH and free T4 levels, and fetal thymus size and thymus–thorax ratio were measured using ultrasound. Exclusion criteria were chronic hypertension, gestational hypertension or eclampsia, multiple pregnancies, infectious diseases, renovascular diseases, diagnosed with hypothyroidism prior to pregnancy and other endocrine disorders, fetal cardiac diseases, and morbid obesity. Data collected included maternal age, gestational week, number of pregnancies, parity, number of living children, thyroid-stimulating hormone (TSH) and Free thyroxine 4 (T4) levels, and fetal thymus measurements (transverse diameter and thymus/thorax ratio). Statistical analyses were performed using the Mann–Whitney U test and logistic regression analysis. The relationships between TSH, thymus diameters, thorax diameters, and the thymus–thorax ratio were evaluated using Spearman’s correlation coefficient. Results: The thymus–thorax ratio was significantly reduced in the hypothyroid group (p = 0.003). Logistic regression analysis identified TSH as an independent risk factor for a low thymus–thorax ratio, with each unit increase in TSH associated with a 1.345-fold higher likelihood of having a low thymus–thorax ratio. A significant negative correlation was found between TSH levels and the TTR ratio (Spearman’s correlation coefficient r = −0.338, p = 0.001). Conclusions: An association was identified between maternal TSH levels and the thymus–thorax ratio, with increasing TSH levels correlating with a decrease in the thymus–thorax ratio. Regular monitoring of thyroid hormone levels during pregnancy and appropriate replacement treatment in cases of deficiency are crucial for optimal fetal thymus development. Further multicenter studies are needed to confirm these findings and investigate the long-term implications of altered fetal thymus development.

Characterizing the diabetes-induced pathological changes of the mouse lung by single-cell RNA sequencing.

Pulmonary disorders are exacerbated by high blood sugar, leading to a disordered immune defense and increased susceptibility to infection. Type 2 diabetes mellitus (T2D) is characterized by insulin resistance and inadequate insulin production. Mechanisms leading to pulmonary alternation due to T2D are not clear. The advancements in single-cell RNA sequencing aid in characterizing the effects of T2D on lungs and its altered mechanisms. Our results first revealed that in late-stage diabetic mice, the number of immune cells in the lungs significantly increased, with these immune cells predominantly being immature polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). At the early stages of diabetes, alveolar cell type I and type II (AT I & II) exhibited a mesenchymal phenotype and showed reduced expression of several key cytokines essential for maintaining lung immunity, including Cxcl15, Cxcl14, and Il34. Additionally, the antigen-presenting cell function of AT II, resulting from the downregulation of several MHC type II proteins, was markedly diminished in diabetic mice. Moreover, decreased expressions of interferon-related genes Ifnar1 and Ifnar2, along with impaired Sftpd expression, compromised lung immunity impairment in diabetic mice. These pathogenic changes contributed to the increased susceptibility and severity of respiratory syncytial virus and tuberculosis in the lung of diabetes. In addition to alveolar cells, pulmonary capillary endothelial cells also exhibited an immature transition phenotype, with a significant increase in angiogenic capacity. Our findings provided a comprehensive exploration of lung pathology under the influence of diabetes and explained the multiple factors impacting lung immunity in diabetic conditions.

Immunophenotyping of Leukocytes in Brain in Hypothyroid Mice.

Hypothyroidism, characterized by inadequate production of thyroid hormones, and malaria, a mosquito-borne infectious disease caused by Plasmodium parasites, are significant health concerns worldwide. Understanding the interplay between these two conditions could offer insights into their complex relationship and potential therapeutic strategies. To induce hypothyroidism, pharmacological inhibition of thyroid hormone synthesis was employed. Subsequently, mice were infected with Plasmodium berghei ANKA to simulate cerebral malaria infection. It needs to monitor the progression of the disease in male mice before it can identify infiltrating immune system populations of interest in the brain by multiparametric techniques such as flow cytometry.

Investigation of Pajanelia longifolia Leaf Extract for Antidiabetic Activity

Diabetes mellitus (DM) is a medical condition characterized by heightened levels of blood sugar, stemming from either inadequate production of insulin or an impaired response to insulin at the cellular level, whether due to a relative or absolute deficiency of the hormone. Traditional herbal remedies have a significant role in the treatment of DM. Pajanelia longifolia, known by the general population as Pajanelia or Tender wild jack has been a component of traditional herbal medicine in India and other Asian countries for the treatment of various ailments. The current research assessed the antidiabetic activity of Pajanelia longifolia leaf extract in streptozotocin (35 mg/kg, oral route) induced diabetic rats. The study utilized an in vivo streptozotocin induced diabetic model and an in vitro rat hemidiaphragm model for assessment of antidiabetic activity. Acute toxicity studies conducted on liposomes of Pajanelia longifolia leaf extract (2000 mg/kg body weight) proved the drug to be non-toxic. The effects of various doses (100, 200 and 400 mg/kg p.o.) of extract were assessed. Glimepiride (2 mg/kg) and insulin (0.25 IU/ml) were used as the standard drugs for in vivo and in vitro studies, respectively. The decrease in blood glucose levels and the elevation of muscle and liver glycogen content in diabetic rats induced by streptozotocin and the increased glucose uptake and glycogen content observed in in vitro rat hemidiaphragm technique proved that Pajanelia longifolia leaf extract has significant antidiabetic activity.

Detection of antibodies to infliximab in routine care: a 4-year French retrospective study.

Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients. ADA and infliximab (IFX) through levels measured by enzyme-linked immunosorbent assay were collected from 505 patients within a period of 4 years. The results indicate that (i) 13.5% of patients produce ADA, (ii) male patients were more likely to produce ADA at levels above 10 000ng/ml than female patients, (iii) ADA levels were lower when associated with immunosuppressant drugs, (iv) there was an inverse relationship between ADA presence and IFX detection, and (v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.

Microplastics as an Emerging Potential Threat: Toxicity, Life Cycle Assessment, and Management.

The pervasiveness of microplastics (MPs) in terrestrial and aquatic ecosystems has become a significant environmental concern in recent years. Because of their slow rate of disposal, MPs are ubiquitous in the environment. As a consequence of indiscriminate use, landfill deposits, and inadequate recycling methods, MP production and environmental accumulation are expanding at an alarming rate, resulting in a range of economic, social, and environmental repercussions. Aquatic organisms, including fish and various crustaceans, consume MPs, which are ultimately consumed by humans at the tertiary level of the food chain. Blocking the digestive tracts, disrupting digestive behavior, and ultimately reducing the reproductive growth of entire living organisms are all consequences of this phenomenon. In order to assess the potential environmental impacts and the resources required for the life of a plastic product, the importance of life cycle assessment (LCA) and circularity is underscored. MPs-related ecosystem degradation has not yet been adequately incorporated into LCA, a tool for evaluating the environmental performance of product and technology life cycles. It is a technique that is designed to quantify the environmental effects of a product from its inception to its demise, and it is frequently employed in the context of plastics. The control of MPs is necessary due to the growing concern that MPs pose as a newly emergent potential threat. This is due to the consequences of their use. This paper provides a critical analysis of the formation, distribution, and methods used for detecting MPs. The effects of MPs on ecosystems and human health are also discussed, which posed a great challenge to conduct an LCA related to MPs. The socio-economic impacts of MPs and their management are also discussed. This paper paves the way for understanding the ecotoxicological impacts of the emerging MP threat and their associated issues to LCA and limits the environmental impact of plastic.

Metabolomic profiling of germinated and non-germinated Lablab purpureus seeds: antioxidant properties and α-amylase inhibitory activities for diabetes management

Diabetes is characterized by prolonged hyperglycemia and disruptions in carbohydrate, lipid, and protein metabolism, stemming from inadequate insulin production, impaired insulin receptor functioning, or a combination of both. Conventional diabetes medications like biguanides and sulphonylureas, are widely used and raise concerns about potential side effects with prolonged usage. In this context, legumes emerge as promising candidates due to their significance in traditional diets globally and associated health benefits. Despite being challenging to digest due to anti-nutritive factors, germination, a simple bioprocessing technique, significantly enhances nutritional aspect of the seeds. This study focuses on Lablab purpureus, an underutilized legume, employing a metabolomic approach to explore compounds in germinated and non-germinated seeds. Metabolomic profiling identified 125 compounds in non-germinated and 80 compounds in germinated seeds, revealing unique compounds in each type with potential health benefits. The study identified therapeutically important metabolites such as alkaloids, flavonoids, terpenoids, and saponin in both the germinated and non-germinated seeds. A notable change in the phytochemical composition (total phenol, flavonoid, and total ascorbic acid content) of germinated seeds was observed compared to the non-germinated seeds flour. An increased fold change (1.15, 1.5 and 1.65) was observed in the total phenol, flavonoid, and total ascorbic acid content in germinated seeds compared to non-germinated seeds, alongside higher antioxidant levels in terms of DPPH, ABTS, and FRAP. The IC50 value for α-amylase inhibitory activity was noted to be 2.05 ± 0.05 mg/ml in germinated samples while 0.79 ± 0.00 mg/ml was observed in the non-germinated Lablab purpureus seeds. Therefore, displaying greater α-amylase inhibitory activity in the non-germinated seeds, possibly due to their unique biochemical composition. Nevertheless, even germinated seeds demonstrated appreciable α-amylase inhibitory activity. Therefore, these findings suggest that germination process significantly influences seed biochemistry and helps to raise the phytochemical composition, while the unique composition of the metabolites in the non-germinated seeds could have impact on the α-amylase inhibitory activity. Thus, study suggests Lablab purpureus as a promising functional food source with diverse health-promoting attributes, particularly in diabetes management.Graphical

A Comprehensive Drug Review on <i>Cuntai Varral Cūranam</i> for its Anti-diabetic Potential on <i>Matumēkam</i> (Type II Diabetes Mellitus)

Diabetes Mellitus (DM) is a chronic metabolic disorder caused by inadequate insulin production by the pancreas or insufficient insulin utilisation by the body. WHO (World Health Organisation) estimates that Non-Communicable Diseases (NCDs) account for 75% of all worldwide fatalities and 2 million death per year account due to diabetes including kidney disease. The prevalence of DM is comparatively higher in lower and middle-income countries than in high-income countries. The IDF states that approximately 10.5% of adults aged 20 to 79 have diabetes, and half of them are unaware of their condition It is estimated that by 2045, the number of adults living with diabetes will rise to 46%. Diabetes Mellitus can be clinically correlated with signs and symptoms of Inippu nīr (NSMC-XGB 1.4) and Matumēkam and its complications stated as in Avattaikal in Siddha text. Traditional plant remedies for diabetes have been considered excellent oral therapeutic options due to their effectiveness, safety and less adverse effects. Cuntai Varral Cūranam (CVC) is the polyherbal formulation prescribed as a single or supplemental drug for gastrointestinal disorders and used in the management of DM and its ailments in practice. This study aims to review the Anti-diabetic efficacy of CVC through its phytochemical, pharmacological aspects, and basic Siddha principle (Mukkurram, cuvai, vīriyam and vipākam) for the ingredients of CVC. The pharmacological actions like anti-diabetic, hypolipidemic, hepatoprotective, nephroprotective, cardioprotective, antioxidant, and anti-microbial activities and the enzyme inhibition pathways of the ingredients were analysed. The result suggested that CVC might be an effective anti-diabetic drug in the management of DM and its complications due to its synergistic effect.

Proof-of-Concept Development of a Point-of-Care Direct Quantification of Glycated Albumin Using a Dual Electrochemical Method Approach

Diabetes mellitus is a prevalent chronic metabolic condition characterized by inadequate insulin production or utilization, leading to elevated blood sugar levels (i.e., hyperglycemia). Effective glycemic control is crucial for preventing long-term complications like cardiovascular disease, kidney disease, neuropathy, and retinopathy. Glycated albumin (GA) is a promising biomarker for glycemic control due to its shorter lifespan and broader reliability compared to glycated hemoglobin (HbA1c), which is the gold standard glycated biomarker widely used in clinical practice. By reflecting the average blood glucose level of the previous 2-3 weeks, as opposed to the 2-3 months of HbA1c, GA allows for better tracking of rapidly evolving conditions. Moreover, it is not affected by hematologic disorders which can bias HbA1c measurements. GA is defined as the fraction of glycated human serum albumin (GHSA) to total human serum albumin (HSA). At present, GHSA is assessed at central laboratories using enzymatic assay kits that rely on spectroscopical measurements and include fructosyl amino-acid oxidase, which requires the proteolytic hydrolysis of GHSA to release fructosyl amino acid. Nevertheless, the need for a pre-treatment of GHSA poses a big challenge in the translation of this technique outside a laboratory setting. Therefore, a point-of-care testing (POCT) platform that minimizes the time gap between measurement and clinical decision-making, and expands the tools available to diabetic subjects for self-monitoring of their blood sugar levels management is needed [1, 2].Aptamers are a type of single-stranded oligonucleotide that are able to selectively interact with a wide range of target molecules. They are chemically synthesized, possess great thermal stability and exhibit regenerable binding [3, 4]. The aptamer against intact GHSA has been reported [5], thus eliminating the need for a pre-digestion of the GHSA and empowering POCT applications. Aptamer-based detection of HSA has also been successfully achieved [6].The clinical relevance for GA as a biomarker relies on the percentage ratio quantification of GHSA to the total HSA present in the plasma. Another problem of current spectroscopic techniques is that GHSA and HSA levels are assessed with two distinct assays (i.e., enzymatic for GHSA and bromocresol purple for HSA), which are difficult to combine into a single platform. Hence, for effective implementation of a POCT or personal sensing device it should be able to measure both GHSA and total HSA on the same unit.In this work we aim to expand on a recent design of our research group [7], in which two aptamer-based extended gate field effect transistor (EGFET) sensors were developed in parallel: one dedicated to GHSA measurement and a second one to quantify total HSA. GHSA was successfully detected in concentrations from 0.1 to 10 μM within 20 minutes, even in presence of bovine serum albumin. Total HSA concentrations ranging from 1 to 17 μM were correctly measured. Furthermore, the linear calibration curves obtained with each sensor allowed to correctly quantify glycation ratios in samples with known and clinically relevant GA levels.The aim of this work is to develop a novel GA sensing technique exploiting a single sensor with dual electrochemical modalities, which are based on square wave voltammetry (SWV) and EGFET. In this scenario, separating the signal contribution of each aptamer from the total is of critical importance. To achieve this, we propose to interrogate each recognition element with a different electrochemical technique. SWV is used to detect the change in electron transfer kinetics of the redox probe covalently attached on one aptamer. For the second aptamer, the EGFET configuration that we have already successfully reported is implemented to detect the non-faradaic contribution of charge variations at the surface of the extended gate. The combination of these two techniques could lead to the dual measurement of GHSA and HSA at the single sensor, enabling the development of an all-in-one POCT platform for glycemic control in diabetic subjects.

Managing Type 2 Diabetes Mellitus via the Regulation of Gut Microbiota: A Chinese Medicine Perspective.

Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder characterized by insulin resistance and inadequate insulin production. Given the increased frequency of T2DM and the health issues it can cause, there is an increasing need to develop alternative T2DM management strategies. One such approach is Chinese Medicine (CM), a complementary therapy widely used in T2DM treatment. Given the emphasis on gut microbiota in current research, studying CM in the treatment of T2DM via gut microbiota modulation could be beneficial. Scope and approach: The use of various CM methods for managing T2DM via gut microbiota modulation is highlighted in this review. Following an introduction of the gut microbiota and its role in T2DM pathogenesis, we will review the potential interactions between gut microbiota and T2DM. Thereafter, we will review various CM treatment modalities that modulate gut microbiota and provide perspectives for future research. Key findings and discussion: In T2DM, Akkermansia, Bifidobacterium, and Firmicutes are examples of gut microbiota commonly imbalanced. Studies have shown that CM therapies can modulate gut microbiota, leading to beneficial effects such as reduced inflammation, improved metabolism, and improved immunity. Among these treatment modalities, Chinese Herbal Medicine and acupuncture are the most well-studied, and several in vivo studies have demonstrated their potential in managing T2DM by modulating gut microbiota. However, the underlying biomolecular mechanisms of actions are not well elucidated, which is a key area for future research. Future studies could also investigate alternate CM therapies such as moxibustion and CM exercises and conduct large-scale clinical trials to validate their effectiveness in treatment.

Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review.

Diabetes mellitus (DM) is a long-term metabolic disorder caused by inadequate production and resistance to insulin. The prevalence of DM is rapidly increasing, with type 2 diabetes (T2D) accounting for more than 90% of cases. Despite new treatments, many patients with T2D do not meet their glycemic targets due to clinical inertia. This review provides an overview of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the management of T2D. The review synthesizes data from clinical trials and meta-analyses on the efficacy, safety, and cost-effectiveness of GLP-1 RAs. It also discusses the mechanisms of action, classification, and barriers to adherence and persistence in therapy. GLP-1 RAs improve glycemic control by lowering A1C levels and promoting weight loss. They have cardioprotective effects and may reduce endothelial inflammation, oxidative stress, and blood pressure. Adherence to GLP-1 RAs is better with once-weekly injections, though gastrointestinal side effects and cost can affect persistence. Semaglutide and liraglutide have shown significant weight reduction, with semaglutide being particularly effective. GLP-1 RAs are cost-effective due to reduced healthcare costs associated with fewer hospitalizations and lower mortality rates. Safety concerns include gastrointestinal issues, pancreatitis, and rare cases of diabetic retinopathy and thyroid C-cell tumors. For clinical practice, GLP-1 RAs represent a valuable option not only for glycemic control but also for weight management and cardiovascular protection. Incorporating GLP-1 RAs into treatment plans can improve patient outcomes, and optimizing dosing regimens and addressing barriers such as cost and side effects are crucial to enhancing patient adherence and long-term treatment success.

Diabetic foot ulcer healing potential of Tagetes erecta L. flower extract on successive administration in alloxan-induced diabetic rats via modulation of liver functions

Diabetes mellitus is a prevalent endocrine disorder characterized by inadequate insulin production by the pancreas or improper utilization of insulin by the body, which imposes severe health complications, including cardiovascular, kidney, and neurological disorders with a high potential of foot ulcers. Globally, diabetes is responsible for over 70 % of limb amputations. Alloxan was used to induce diabetes in rats while foot ulcers were induced by the excision method in diabetic rats. Diabetes was confirmed by measuring the parameters like blood glucose, body weight changes, urine excretion, and other biomarker levels after oral administration of Tagetes erecta L. flower extract (TEFE) at different doses. During the work, it was observed that TEFE demonstrated a dose-dependent effect on blood sugar level from 370.2 mg/dl to 113.00 mg/dl and healing of diabetic foot ulcers in a 13 days animal model (p < 0.01). There is significant decline in SGOT, SPGT and ALP levels when compared with diseased group animals. Decrease in wound size was observed when TEFE was administered to diabetic foot ulcer rats. These exciting results steered to enumerate the possible role of TEFE in Diabetes mellitus through a panel of mechanisms of action like inhibition of free radical generation, modulation of liver enzymes and metabolism of glucose etc. The above findings support the hypoglycaemic and diabetic foot ulcer healing potential of TEFE. Moreover, further investigation is required to completely understand the possible mechanism of TEFE.

A comparative study between metformin and insulin on biochemical variables in diabetic patients

Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels due to inadequate insulin production or inefficient use of insulin by the body's cells. It poses significant health risks, including cardiovascular disease and kidney damage, affecting millions worldwide. Management involves careful monitoring of blood glucose levels, lifestyle modifications, and sometimes insulin therapy to maintain optimal health.so Metformin is a widely prescribed oral medication used to manage type 2 diabetes by improving insulin sensitivity.The study was conducted in the period from February to March 2023, where a blood sample was collected from males aged from 30 to 50 years. The samples were divided into 15 healthy people as control, 12 samples with diabetes type 2, 12 samples with diabetes type 2 who are treated with metformin, and 12 samples with diabetes type 2 who are treated with insulin injections. The samples were separated in a centrifuge at 4000 rpm, then divided to 10 fractions and stored in the freezer until biochemical tests were performed for the study.The results showed A significant increase at Glucose and HbA1C in all groups compared with control. So total cholesterol and low density lipoprotein decrease in diabetic and treatment with insulin injections compared all groups, triglycerides and very low density lipoprotein increase in all diabetic groups compared with control. Alanin trans aminase showed decrease value in diabetic group and treatment with insulin injections compared with all groups but aspartate trans aminase showed result opposite. Aim of studySince diabetes is a chronic disease, it is necessary to know the effects of the most famous treatments taken by diabetics, which are metformin and insulin, on the lipid profile and liver and kidney functions.

Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

Background: Inadequate production of immunoglobulin G (IgG) antibodies renders patients with primary immunodeficiency susceptible to infection by numerous pathogens, some of which can lead to severe asthma exacerbation and possible death. These patients who are immunocompromised are often reliant on intravenous immunoglobulin (IVIG) therapies, which provide passive antibodies against various respiratory pathogens, including measles virus and encapsulated bacteria. Objective: We conducted a subanalysis of data from a multicenter, multinational, phase III, open-label bioequivalence study to compare protective concentrations of IgG antibodies provided by a 5% and a 10% IVIG product in patients with primary immunodeficiency. Methods: Patients on stable 21- or 28-day regimens of previous IVIG products were assigned to receive study treatment (adults: 5% IVIG and 10% IVIG; children: 10% IVIG) at doses of 300-800 mg/kg per infusion. Trough concentrations of total IgG, IgG subclasses, measles-neutralizing antibodies, and IgG against Haemophilus influenzae type b and Streptococcus pneumoniae serotypes were evaluated. Results: A total of 48 patients (33 adults ages 16-55 years; 15 children ages 2-15 years) were enrolled and received treatment. No statistically significant differences in trough concentrations of total IgG, IgG subclasses, measles-neutralizing antibodies, or IgG directed at encapsulated bacteria were observed between the 5% and 10% formulations in analyses by age (adult or pediatric) or infusion schedule (every 21 or 28 days). All evaluated patients had trough IgG concentrations above accepted thresholds for protection against disease. Conclusion: These findings support the conclusion that, at dose levels and infusion schedules prescribed in clinical practice, this 5% and 10% IVIG product provided consistent, predictable, and bioequivalent IgG concentrations for adult and pediatric patients with primary immunodeficiency disease. Both formulations delivered trough antibody concentrations of total IgG, measles-neutralizing antibodies, and antibodies against encapsulated bacteria that are above thresholds accepted as protective.Clinical trial NCT01963143, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>.

Evaluation of Lipid profile and Uric acid level in Type II Diabetes mellitus

T2DM is characterized primarily by pancreatic beta cell loss, inadequate insulin production, or insulin resistance in body cells, among other causes. T2DM is related to a variety of other indications and symptoms including coronary heart disease, kidney illness, eye abnormalities, peripheral vascular disease, digestive system diseases, high blood pressure and depression. Lipid abnormalities are common in persons with type 2 diabetes and prediabetes, although the pattern of the different lipids may vary between ethnic groups, economic levels and access to health care. Uric acid is produced during nucleotide and adenosine triphosphate (ATP) metabolism and is the end product of human purine. Biologically, uric acid plays a significant role in developing insulin resistance in animal models by reducing the bioavailability of nitric oxide which is required for insulin-stimulated glucose uptake. This study aimed to evaluate the lipid profile and uric acid level in patients with Type 2 diabetes mellitus. Blood samples were collected from 50 control and diabetic patients. The lipid profile and uric acid level were estimated by the kit method. Significantly higher levels of total cholesterol, triglycerides, HDL and LDL were observed in the diabetic group compared to the controls. Significantly low levels of serum uric acid and higher blood glucose levels were observed between normal and diabetic subjects. Diabetic dyslipidemia is curable if identified early. It can be improved by regulating glycemic (glucose) levels, lowering free fatty acids and increasing VLDL production by the liver. It can also be treated with weight loss, exercise, smoking cessation, a nutritious diet and pharmaceutical therapy.

Antidiabetic Effect of Ethanol Extract of Keji beling Leaves (Strobhilantes crispa) in Rats Induced by Streptozotocin

Diabetes Mellitus (DM) type 2 is a chronic disease characterized by increased glucose levels in the body due to insulin resistance or inadequate insulin production. This study aims to determine the antidiabetic potential of keji beling ( Strobhilantes crispa) leaf extract. This research is different from other studies which used Alloxan as a diabetes inducer. In this study, Streptozotocin was used as a DM inducer. After treatment, information was obtained that keji beling (S. crispa) extract could reduce blood glucose levels in type 2 DM rats. Experimental research used 30 male Wistar rats divided into six groups consisting of normal group, negative control (HFD and Streptozotocin), positive control (Glibenclamide), dose group I (150 mg/kg BW), dose II (300 mg/ kg BW), and dose III (450 mg/kg BW). Based on the research results, it is known that S.crispa leaf extract can reduce blood glucose levels in mice induced by Streptozotocin and has the potential to act as an antihyperglycemic in type 2 DM.

Evaluation of traditional Chinese medicine tea bag TBDESJS in patients with Sjögren's syndrome and dry eye syndrome: A phase II pilot study.

Sjögren's syndrome (SJS) and dry eye syndrome (DES) are characterized by ocular dryness from inadequate tear production or excessive evaporation. To evaluate the effectiveness of TBDESJS (Chun-Yu-Ching-Hua-Yin, CYCHY), a TCM tea bag, in treating SJS and DES patients compared with healthy controls (NHC). This phase II pilot study included 100 participants (60 SJS, 30 DES, 10 NHC) across 8 weeks, assessing changes in Schirmer's test, OSDI, ESSPRI, PSQI, FIRST, and artificial tear usage, using repeated measurement ANOVA and Tukey's honestly significant difference (HSD) for analysis. Total 97 subjects completed the trial, for the left eye (OS) of Schirmer's test, significant improvements at 4, and 8 weeks were observed in SJS (0.13 ± 0.43-5.77 ± 2.87, and 7.60 ± 4.84 mm) and DES (0.21 ± 0.41-6.21 ± 2.97, and 7.86 ± 3.47 mm) (all p < .001). For the right eye (OD), significant improvements were observed in SJS (0.13 ± 0.39-6.77 ± 4.53, and 8.79 ± 5.92 mm) and DES (0.34 ± 0.55-6.59 ± 2.50, and 8.24 ± 3.42 mm) (all p < .001). Secondary outcomes showed reduced the dryness of ESSPRI scores in SJS (6.37 ± 1.97-5.57 ± 1.79, p < .001) and DES (6.10 ± 1.97-5.28 ± 2.23, p < .05). PSQI global scores improved significantly in all groups at 8 weeks (p < .05). Artificial tear usage decreased in SJS (4.93 ± 2.45-1.00 ± 0.82 times/day), DES (4.47 ± 1.99-0.66 ± 0.67 times/day) (all p < .001). No serious adverse events in this study. TBDESJS significantly improved tear production, ocular dryness, and sleep quality, indicating potential neural regulation, anti-inflammatory and immunomodulatory benefits. These findings advocate for TBDESJS (Chun-Yu-Ching-Hua-Yin, CYCHY)'s comprehensive therapeutic value in SJS and DES treatment, emphasizing the need for further research to understand long-term effects and mechanisms.

Self-enhancement of bioenergy recovery from anaerobically digesting WAS with novel iron-based metal-organic framework assistance: Insights into electron transfer and metabolic pathways

Inadequate methane production and insufficient hydrolysis-acidification activity impede the practical application of anaerobic digestion (AD) of waste activated sludge (WAS). Recently, metal-organic framework (MOF) materials attains promising capability of controlling proton/electron transfer in AD processes. This study used a typical iron-based MOF and MIL-88A(Fe) to improve the methane production via digesting WAS. These materials were prepared via a one-step hydrothermal method. The findings indicated that the addition of 150 mg MIL-88A(Fe)/g WAS VS resulted in a 57.23% increase in accumulated methane production and a 43.84% increase in daily maximum methane production. The methane production rate (Rmax) also increased from 22.25 to 29.14 mL/g VS/d. The enhanced electron transfer capacity, improved hydrolysis of WAS, boosted acetate generation, and mitigated accumulation of volatile fatty acids (VFAs) collectively contributed to the better methane yield in the MIL-88A(Fe)-added system. The significant enrichment of Methanobacterium and Methanosaeta along with the up-regulation of key methanogenesis enzyme-encoding genes jointly suggested that the CO2 reduction and methanogenesis were strengthened. Moreover, MIL-88A(Fe) stimulated the production of c-type cytochrome and e-pili, facilitating direct interspecies electron transfer (DIET) between norank-f-SC-I-84 and Methanobacterium. This study provided new solutions for improving methane production and offered insights into the mechanism of enhanced methanogenesis of AD in the presence of MIL-88A(Fe).

The effect of antidiabetic drugs on bone metabolism: a concise review.

Diabetes mellitus (DM) is a complex metabolic disorder characterized by chronic hyperglycemia, which derives from either insufficient insulin production [type 1 diabetes mellitus (T1DM)] or both impaired insulin sensitivity along with inadequate insulin production [type 2 diabetes mellitus (T2DM)] and affects millions of people worldwide. In addition to the adverse effects of DM on classical target organs and tissues, skeletal health can also be adversely affected. There is considerable evidence linking DM with osteoporosis. The fracture risk in patients with DM differs upon the type of diabetes, and it appears to be related to the type of anti-diabetic treatment. Antidiabetic drugs may have various effects on bone health. Most of them have neutral or even favorable effects on bone metabolism with the exception of thiazolidinediones (TZDs). Some studies suggest that TZDs may have negative impact on bone health by decreasing bone formation and increasing the fracture risk. There are also limited studies linking the use of canagliflozin, a Sodium-glucose contransporter-2 inhibitor (SGLT2i), with increased fracture risk. On the other hand, therapies that are based on incretin effect, like Dipeptidyl peptidase-4 inhibitors (DPP-4i) and Glucagon-like peptide-1 receptor agonizts (GLP-1RAs) might have positive effects on bone health by promoting bone formation. Herein we review the impact of antidiabetic drugs on bone health, highlighting the potential benefits and risks associated with these medications in an attempt to contribute to the development of personalized treatment strategies for individuals with DM.

HUBUNGAN SENAM PROLANIS TERHADAP PENURUNAN KADAR GULA DARAH SEWAKTU PADA PASIEN DIABETES MELLITUS TIPE 2 DI PUSKESMAS SEI LEKOP

Background : Type 2 diabetes mellitus is a chronic metabolic disease characterized by elevated blood glucose levels in the body due to insulin resistance or inadequate insulin production. The purpose of this study is to investigatethe relationship between physical activity and blood sugar levels in patients with type 2 Diabetes Mellitus who participated in the PROLANIS program at the Sei Lekop Community Health Center in 2023. Methods : This study is an observational research with an analytical cohort design. Data collection was obtained from the medical records of patients with type 2 diabetes mellitus who are registered under BPJS. The data analysis methods include univariate analysis and bivariate analysis, with a standard error of estimate set at 5% or 0.05 Results : The results of the Wilcoxon test showed that PROLANIS exercise had a relationship with reducing blood sugar levels during type 2 diabetes mellitus patients at the Sei Lekop Community Health Center in 2023. The results of the Wilcoxon test were p = 0.001. Conclusion : Based on the results of this study, it can be concluded that there is a relationship between PROLANIS exercise and random blood sugar levels in patients with type 2 diabetes mellitus at Sei Lekop Health Center in 2023 Keywords : Diabetes Mellitus, Blood Glucose Levels, and PROLANIS Exercise.